ADAA’s 2019 Conference to Feature Sessions on Ketamine, the FDA-Approved Nasal Spray for Treatment Resistant - EIN News

ADAA’s 2019 Conference to Feature Sessions on Ketamine, the FDA-Approved Nasal Spray for Treatment Resistant  EIN NewsMore than 1400 international researchers and clinicians specializing in anxiety, depression, and related disorders will convene in Chicago later this month for.